
Archit Organosys (ARCHITORG) | Financial Analysis & Statements
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Mar 2025Income Metrics
Revenue
431.8M
Gross Profit
115.3M
26.71%
Operating Income
29.5M
6.84%
Net Income
20.2M
4.67%
Balance Sheet Metrics
Total Assets
1.2B
Total Liabilities
537.1M
Shareholders Equity
692.1M
Debt to Equity
0.78
Cash Flow Metrics
Revenue & Profitability Trend
Archit Organosys Income Statement From 2021 to 2025
Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
---|---|---|---|---|---|
Revenue | 1.3B | 1.1B | 1.2B | 1.4B | 943.4M |
Cost of Goods Sold | 893.4M | 894.5M | 924.8M | 1.0B | 709.9M |
Gross Profit | 362.6M | 209.1M | 285.0M | 362.1M | 233.4M |
Gross Margin % | 28.9% | 18.9% | 23.6% | 26.3% | 24.7% |
Operating Expenses | |||||
Research & Development | - | - | - | - | - |
Selling, General & Administrative | - | 71.4M | 74.3M | 65.9M | 38.5M |
Other Operating Expenses | 161.9M | 14.1M | 6.1M | 130.7M | 18.4M |
Total Operating Expenses | 161.9M | 85.4M | 80.4M | 196.5M | 56.9M |
Operating Income | 70.3M | 12.0M | 147.3M | 119.5M | 77.2M |
Operating Margin % | 5.6% | 1.1% | 12.2% | 8.7% | 8.2% |
Non-Operating Items | |||||
Interest Income | - | 13.2M | 3.1M | 10.7M | 4.9M |
Interest Expense | 25.8M | 25.8M | 21.6M | 24.4M | 31.7M |
Other Non-Operating Income | - | - | - | - | - |
Pre-tax Income | 75.4M | 43.2M | 153.6M | 114.3M | 46.8M |
Income Tax | 24.9M | 10.5M | 40.1M | 31.9M | -3.2M |
Effective Tax Rate % | 33.0% | 24.2% | 26.1% | 28.0% | -6.9% |
Net Income | 50.5M | 32.8M | 113.5M | 82.3M | 50.1M |
Net Margin % | 4.0% | 3.0% | 9.4% | 6.0% | 5.3% |
Key Metrics | |||||
EBITDA | 160.6M | 86.6M | 201.4M | 185.5M | 118.1M |
EPS (Basic) | - | ₹1.60 | ₹5.53 | ₹4.01 | ₹3.33 |
EPS (Diluted) | - | ₹1.60 | ₹5.53 | ₹4.01 | ₹3.33 |
Basic Shares Outstanding | - | 20520723 | 20520723 | 20527431 | 15020723 |
Diluted Shares Outstanding | - | 20520723 | 20520723 | 20527431 | 15020723 |
Income Statement Trend
Archit Organosys Balance Sheet From 2021 to 2025
Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
---|---|---|---|---|---|
Assets | |||||
Current Assets | |||||
Cash & Equivalents | 681.0K | 38.2M | 50.2M | 53.5M | 38.1M |
Short-term Investments | 3.8M | 4.0M | 3.6M | 9.5M | 9.7M |
Accounts Receivable | 230.5M | 222.3M | 373.6M | 273.5M | 250.0M |
Inventory | 43.0M | 34.4M | 33.8M | 59.4M | 35.4M |
Other Current Assets | 8.0M | 13.3M | 8.3M | 9.1M | 6.9M |
Total Current Assets | 615.0M | 414.9M | 479.4M | 429.3M | 341.7M |
Non-Current Assets | |||||
Property, Plant & Equipment | 539.7M | 596.6M | 504.6M | 450.5M | 476.7M |
Goodwill | 0 | 0 | 0 | 0 | 2.0K |
Intangible Assets | - | - | - | - | 2.0K |
Long-term Investments | - | - | - | - | - |
Other Non-Current Assets | -10.0K | 2.0M | 13.4M | 1.0K | 1.6M |
Total Non-Current Assets | 614.2M | 667.5M | 722.3M | 606.3M | 533.2M |
Total Assets | 1.2B | 1.1B | 1.2B | 1.0B | 874.9M |
Liabilities | |||||
Current Liabilities | |||||
Accounts Payable | 217.9M | 134.6M | 231.9M | 135.6M | 146.1M |
Short-term Debt | 226.3M | 181.7M | 167.7M | 205.5M | 183.1M |
Current Portion of Long-term Debt | - | - | - | - | - |
Other Current Liabilities | 5.0M | 208.0K | 5.8M | 2.6M | 2.1M |
Total Current Liabilities | 457.0M | 342.6M | 419.0M | 376.0M | 342.8M |
Non-Current Liabilities | |||||
Long-term Debt | 49.6M | 82.7M | 146.3M | 134.2M | 124.1M |
Deferred Tax Liabilities | 28.1M | 13.2M | 17.6M | 3.7M | 0 |
Other Non-Current Liabilities | - | - | 39.0K | - | - |
Total Non-Current Liabilities | 80.1M | 98.3M | 164.9M | 140.6M | 126.7M |
Total Liabilities | 537.1M | 440.9M | 584.0M | 516.6M | 469.5M |
Equity | |||||
Common Stock | 205.2M | 205.2M | 205.2M | 205.2M | 150.2M |
Retained Earnings | - | 249.8M | 225.6M | 127.5M | 55.5M |
Treasury Stock | - | - | - | - | - |
Other Equity | - | - | - | - | - |
Total Shareholders Equity | 692.1M | 641.5M | 617.8M | 518.9M | 405.4M |
Key Metrics | |||||
Total Debt | 276.0M | 264.4M | 314.1M | 339.7M | 307.2M |
Working Capital | 157.9M | 72.2M | 60.4M | 53.2M | -1.1M |
Balance Sheet Composition
Archit Organosys Cash Flow Statement From 2021 to 2025
Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
---|---|---|---|---|---|
Operating Activities | |||||
Net Income | 75.4M | 43.2M | 153.6M | 114.3M | 46.8M |
Depreciation & Amortization | - | - | - | - | - |
Stock-Based Compensation | - | - | - | - | - |
Working Capital Changes | -3.3M | 140.2M | -66.8M | -45.9M | -27.4M |
Operating Cash Flow | 70.4M | 195.5M | 103.7M | 87.7M | 47.5M |
Investing Activities | |||||
Capital Expenditures | -3.6M | 46.7M | -116.3M | -107.4M | -30.2M |
Acquisitions | -4.3M | 810.0K | 0 | - | - |
Investment Purchases | -915.0K | -29.5M | -18.0M | -11.0M | -3.0M |
Investment Sales | - | 10.9M | - | 0 | 0 |
Investing Cash Flow | -8.8M | 28.9M | -134.3M | -118.4M | -33.2M |
Financing Activities | |||||
Share Repurchases | - | - | - | - | - |
Dividends Paid | -5.0K | -9.9M | -14.4M | -10.3M | - |
Debt Issuance | - | - | - | - | - |
Debt Repayment | - | - | - | - | - |
Financing Cash Flow | 44.3M | 11.2M | -14.3M | 31.0M | 13.8M |
Free Cash Flow | 180.2M | 83.0M | 12.2M | -2.2M | 79.5M |
Net Change in Cash | 105.9M | 235.7M | -44.8M | 246.0K | 28.1M |
Cash Flow Trend
Archit Organosys Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
19.00
Price to Book
1.39
Price to Sales
0.73
Profitability Ratios
Profit Margin
4.62%
Operating Margin
7.98%
Return on Equity
7.30%
Return on Assets
4.11%
Financial Health
Current Ratio
1.35
Debt to Equity
39.88
Beta
-0.35
Per Share Data
EPS (TTM)
₹2.46
Book Value per Share
₹33.62
Revenue per Share
₹63.99
Peer Financial Comparison
Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
---|---|---|---|---|---|---|
architorg | 958.9M | 19.00 | 1.39 | 7.30% | 4.62% | 39.88 |
Navin Fluorine | 255.9B | 69.93 | 9.44 | 10.99% | 13.90% | 55.85 |
Deepak Nitrite | 253.2B | 41.67 | 4.70 | 11.85% | 7.58% | 23.36 |
India Glycols | 50.0B | 20.49 | 2.21 | 10.24% | 6.35% | 83.85 |
Styrenix Performance | 46.4B | 20.53 | 3.97 | 20.14% | 7.00% | 34.02 |
Gujarat Alkalies | 40.4B | 70.12 | 0.67 | -1.08% | -0.82% | 9.30 |
Financial data is updated regularly. All figures are in the company's reporting currency.